Summary of Key Points Core Viewpoint - The company has conducted a self-inspection of its tax obligations and identified a need to pay additional corporate income tax and late fees totaling 4.5322 million yuan due to discrepancies in the tax treatment of convertible bonds [1][3]. Group 1: Tax Payment Details - The company has completed the payment of the aforementioned tax and late fees, and there are no administrative penalties involved [2]. - The total amount due for corporate income tax and late fees is 4.5322 million yuan [1]. Group 2: Financial Impact - According to relevant accounting standards, the payment of these taxes and late fees does not constitute a prior accounting error and will not require restatement of previous financial data [3]. - The payment will be recorded in the company's 2025 financial results, expected to reduce the net profit attributable to shareholders by 4.5322 million yuan for the year 2025 [3].

来源:金融界 8月13日主力资金净流入210.04万元，占流通市值的0.1%。近五日主力资金净流出827.93万元，占流通 市值的0.38%。 风险提示：股市有风险，投资需谨慎。 瑞丰高材8月13日股价报11.33元，较前一交易日下跌0.17元，跌幅1.48%。当日成交量为74761手，成交 额达0.85亿元。 该公司主要从事PVC助剂、工程塑料助剂等产品的研发、生产和销售。瑞丰高材于2011年在创业板上 市，最新总市值为28.37亿元。 公司近期公告显示，因可转换公司债券利息费用的税会处理差异，需补缴企业所得税592.47万元及滞纳 金75.25万元，合计667.71万元。该笔款项已补缴完毕，预计将影响公司2025年度净利润约667.71万元。 此外，公司前董秘赵子阳因涉嫌内幕交易被证监会立案调查，公司表示该调查与日常经营无关。 ...

Group 1 - The core issue involves tax self-inspection results disclosed by two companies, Daon Co., Ltd. and Huason Pharmaceutical, due to discrepancies in the tax treatment of convertible bond interest expenses [1][3][7] - Daon Co., Ltd. needs to pay a total of 16.15 million yuan, which includes 11.87 million yuan in corporate income tax and 4.27 million yuan in late fees [3][4] - Huason Pharmaceutical is required to pay a total of 10.02 million yuan, comprising 7.17 million yuan in corporate income tax and 2.84 million yuan in late fees [1][7][8] Group 2 - Both companies confirmed that the tax payment issues do not involve prior accounting errors and will not require restatement of previous financial data [4][8] - The tax payments will impact the net profit attributable to shareholders for the year 2025, with Daon Co., Ltd. expecting a reduction of 16.15 million yuan and Huason Pharmaceutical anticipating a reduction of 10.02 million yuan [4][8] - The companies have emphasized their commitment to enhancing supervision and management of tax-related matters to protect the interests of shareholders [8]